Response criteria for clinical trials in systemic lupus erythematosus

Abstract

Keywords

Get full access to this article

View all access options for this article.

References

Fortin PR , Stucki G. , Katz JN Measuring relevant change: an emerging challenge in rheumatologic clinical trials. Arthritis Rheum 1995: 1027-1030.

Liang MH Towards more informative pilot studies with new anti-rheumatic drugs . Agents and Actions 44 (suppl. 119), 77-81.

Redelmeier DA , Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Int Med 1993; 153: 1337-1342.

Kopec JA et al. The Quebec back pain disability scale: measurement properties . Spine 1995 (in press).

Liang MH et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.

Bombardier C. et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.

Hay EM et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993 ; 86: 447-458.

Petri M. , Hellmann D. , Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 9: 53-59.

Vitali C. et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of The European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 541-547.